IMPDH2 and colorectal carcinoma: Thus, we hypothesize that purine reprogramming is a novel mechanism of oxaliplatin resistance and that inhibiting purine metabolism by targeting the key enzyme IMPDH2 may be a potential therapeutic approach for reversing oxaliplatin resistance in CRC.